Signati wins FDA IDE for pivotal Separo vasectomy trial

Signati Medical has moved its Separo vasectomy platform into a more consequential regulatory phase, announcing on June 2, 2026, that the FDA approved an IDE for a pivotal clinical study of the investigational device. The study will compare Separo, a vessel sealing system designed specifically for vasectomy, against mucosal cautery vasectomy in a randomized, controlled, open-label, multicenter non-inferiority trial at up to five U.S. institutions, with planned enrollment of 120 adult male participants. (globenewswire.com)

The company has been building toward this point for several years. Earlier coverage from Urology Times said Signati had already generated preclinical GLP data and completed a small FDA IDE study, then filed for de novo market clearance. That earlier human study, listed on ClinicalTrials.gov as NCT06402773, evaluated the Signati system for vasectomy and enrolled eight patients. (urologytimes.com)

That early evidence base was small, but directionally encouraging. In the Urology Times interview, principal investigator Matthew J. Mutter, MD, said all eight patients in the IDE study reached azoospermia or rare non-motile sperm by six months, with no device-related adverse events reported. An abstract describing the early human work reported short sealing times, low pain scores, and no adverse events in the initial treated patients, though it also disclosed that authors had consulting, employment, or shareholder ties to Signati Medical. (urologytimes.com)

The new pivotal study is designed around the endpoint that matters most in vasectomy follow-up: post-vasectomy semen analysis. Signati said success will be defined as azoospermia or rare non-motile sperm at or below 100,000 non-motile sperm per mL within six months, which aligns with American Urological Association guidance on when patients may stop using other contraception after vasectomy. That alignment matters because it gives the trial a clinically familiar benchmark rather than a company-created endpoint. (globenewswire.com)

Industry reaction so far has centered less on headline-grabbing efficacy claims and more on workflow. In comments published by Urology Times, Mutter said the device could allow a urologist to perform the procedure without an assistant and move patients through the office more quickly. That kind of positioning is notable because Signati is not only arguing that Separo can work, but that it may reduce technical variability and improve procedural efficiency, themes the company also emphasized in its announcement. (urologytimes.com)

Why it matters: For veterinary professionals, this is adjacent rather than directly practice-changing, but it’s a useful regulation story because it shows how companies increasingly frame pivotal trials around more than safety and effectiveness alone. Signati is openly saying the trial was built to support future guideline inclusion and payer adoption, underscoring how evidence strategy, reimbursement strategy, and workflow claims are now tightly linked in device development. That playbook is familiar across both human and animal health: if a company wants durable adoption, it usually needs comparative data, operational value, and a reimbursement narrative, not just an FDA milestone. (globenewswire.com)

It’s also worth keeping the limitations in view. The company’s announcement is a press release, the prior human dataset was very small, and the device remains investigational and unavailable for sale. Until pivotal data are produced and reviewed, the real questions are whether Separo can match standard vasectomy techniques on effectiveness, whether the workflow advantages hold up across multiple sites and operators, and whether any benefits are meaningful enough to change practice patterns. (globenewswire.com)

What to watch: The next markers are straightforward: site activation, enrollment progress, any public protocol details beyond the company release, and eventually whether the pivotal trial supports a renewed or updated FDA clearance submission. If the study is positive, the more interesting second-order signal may be whether professional societies and payers treat the evidence as sufficient for broader adoption. (globenewswire.com)